Efficacy, Safety and Tolerability Study of Glatiramer Acetate in Subjects With Multiple Sclerosis

Study Title
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Teva Identifier
GA-MS-302 | 2011-005550-57
ClinicalTrials.gov Identifier
NCT01578785
Study Status
Terminated
Trial Condition(s)
Relapsing-Remitting Multiple Sclerosis
Interventions
Drug: Glatiramer Acetate | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 55 Years
Trial Duration
03/01/2012 - 11/01/2012
Phase
Phase 3

Study Type

Interventional